Evidence map›Paper›PMID 33647246›Full record

Trial reportThe Lancet. Neurology2021

Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.

Mikael Mazighi, Sebastien Richard, Bertrand Lapergue, Igor Sibon, Benjamin Gory, Jerome Berge, Arturo Consoli, Julien Labreuche, Jean-Marc Olivot, Joseph Broderick and 20 more

3 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The Lancet. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 111 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 9 pooled it
23.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03160677 nacompletednot on this map

Comparison of Two Strategies for Blood Pressure Control in the Setting of Acute Ischemic Stroke to Reduce Cerebral Hemorrhage After Thrombectomy: Systolic Blood Pressure Target of Less Than 130 mmHg vs Less Than 185 mmHg, for 24 Hours Following Reperfusion, in Patients With Cerebral Infarction Due to Occlusion of the Anterior Circulation

TypeinterventionalSponsorFondation Ophtalmologique Adolphe de RothschildRan2017 to 2020Enrolled320ConditionsAcute Stroke, Blood Pressure, Cerebral HemorrhageArmsSystolic blood pressure target < 130 mm Hg, Systolic blood pressure target < 185 mm Hg
NCT05282290 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Prevention and Treatment of Reperfusion Injury After Mechanical Thrombectomy in Acute Ischemic Stroke

TypeinterventionalSponsorXijing HospitalRan2022 to 2024Enrolled120ConditionsStroke PatientsArmsAntihypertensive drugs (no restriction on the type of drugs)
NCT07527013 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)

TypeinterventionalSponsorBeijing Tiantan HospitalRan2026 to 2028Enrolled544ConditionsEndovascular Therapy, Acute Ischaemic Stroke, Collateral Circulation, Blood Pressure ManagementArmsStratified Blood Pressure Management
3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 9 syntheses or guidelines pooled it, 213 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Blood pressure targets after successful reperfusion in mechanical thrombectomy for acute ischemic stroke: an updated systematic review and meta-analysis of randomized clinical trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Systolic blood pressure targets after successful endovascular thrombectomy: a network meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 9 institutions in 3 countries.

Mikael MazighiDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; Université de Paris, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: mmazighi@for.paris.
Sebastien RichardDepartment of Neurology, Stroke Unit, University Hospital of Nancy, Nancy, France; Université de Lorraine, INSERM, Nancy, France.
Bertrand LapergueDepartment of Neurology, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France.
Igor SibonStroke Unit, CHU Bordeaux, Université de Bordeaux, Bordeaux, France.
Benjamin GoryDepartment of Diagnostic and Therapeutic Neuroradiology, CHRU-Nancy, Université de Lorraine, Nancy, France; Université de Lorraine, IADI, INSERM U1254, Nancy, France.
Jerome BergeInterventional and Diagnostic Neuroradiology Department, Bordeaux University Hospital, Bordeaux, France.
Arturo ConsoliDepartment of Neuroradiology, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France.
Julien LabreucheDepartment of Biostatistics, University Lille, CHU de Lille, Lille, France.
Jean-Marc OlivotStroke Unit, Toulouse University Hospital, Toulouse, France.
Joseph BroderickDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Alain DuhamelDepartment of Biostatistics, University Lille, CHU de Lille, Lille, France.
Emmanuel TouzeDepartment of Neurology, Université Caen Normandie, INSERM U1237, CHU Caen Normandie, Caen, France.
Adnan I QureshiDepartment of Neurology, University of Missouri, Women's and Children's Hospital, Columbia, MO, USA.
Amélie YavchitzDepartment of Clinical Research, Rothschild Foundation Hospital, Paris, France.
Simon EscalardDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Jean-Philippe DesillesDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; Université de Paris, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.
Hocine RedjemDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Stanislas SmajdaDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Robert FahedDivision of Neurology and Department of Medical Imaging, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Solène HébertDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Benjamin MaïerDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; Université de Paris, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.
François DelvoyeDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Perrine BoursinDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Malek Ben MaachaDepartment of Clinical Research, Rothschild Foundation Hospital, Paris, France.
Michael ObadiaStroke Unit, Rothschild Foundation Hospital, Paris, France.
Candice SabbenStroke Unit, Rothschild Foundation Hospital, Paris, France.
Raphael BlancDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.
Julien SavatovskyDiagnostic Imaging and Radiology Department, Rothschild Foundation Hospital, Paris, France.
Michel PiotinDepartment of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; Laboratory of Vascular Translational Science, INSERM, Paris, France; FHU NeuroVasc, Assistance Publique-Hôpitaux de Paris, Paris, France.
BP-TARGET investigators
Fondation de Rothschild · FRInserm · FRUniversité de Versailles Saint-Quentin-en-Yvelines · FRUniversité de Bordeaux · FRUniversité de Lille · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversity of Cincinnati Medical Center · USUniversity of Missouri Women's and Children's Hospital · USUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh systolic blood pressure after successful endovascular therapy for acute ischaemic stroke is associated with increased risk of intraparenchymal haemorrhage. However, no randomised controlled trials are available to guide optimal management. We therefore aimed to assess whether an intensive systolic blood pressure target resulted in reduced rates of intraparenchymal haemorrhage compared with a standard systolic blood pressure target.

methodsWe did a multicentre, open-label, randomised controlled trial at four academic hospital centres in France. Eligible individuals were adults (aged ≥18 years) with an acute ischaemic stroke due to a large-vessel occlusion that was successfully treated with endovascular therapy. Patients were randomly assigned (1:1) to either an intensive systolic blood pressure target group (100-129 mm Hg) or a standard care systolic blood pressure target group (130-185 mm Hg), by means of a central web-based procedure, stratified by centre and intravenous thrombolysis use before endovascular therapy. In both groups, the target systolic blood pressure had to be achieved within 1 h after randomisation and maintained for 24 h with intravenous blood pressure lowering treatments. The primary outcome was the rate of radiographic intraparenchymal haemorrhage at 24-36 h and the primary safety outcome was the occurrence of hypotension. Analyses were done on an intention-to-treat basis. BP-TARGET is registered with ClinicalTrials.gov, number NCT03160677, and the trial is closed at all participating sites.

findingsBetween June 21, 2017, and Sept 27, 2019, 324 patients were enrolled in the four participating stroke centres: 162 patients were randomly assigned to the intensive target group and 162 to the standard target group. Four (2%) of 162 patients were excluded from the intensive target group and two (1%) of 162 from the standard target group for withdrawal of consent or legal reasons. The mean systolic blood pressure during the first 24 h after reperfusion was 128 mm Hg (SD 11) in the intensive target group and 138 mm Hg (17) in the standard target group. The primary outcome was observed in 65 (42%) of 154 patients in the intensive target group and 68 (43%) of 157 in the standard target group on brain CT within 24-36 h after reperfusion] (adjusted odds ratio 0·96, 95% CI 0·60-1·51; p=0·84). Hypotensive events were not significantly different between both groups and occurred in 12 (8%) of 158 patients in the intensive target and five (3%) of 160 in the standard target group. Mortality within the first week after randomisation occurred in 11 (7%) of 158 patients in the intensive target group and in seven (4%) of 160 in the standard target group.

interpretationAn intensive systolic blood pressure target of 100-129 mm Hg after successful endovascular therapy did not reduce radiographic intraparenchymal haemorrhage rates at 24-36 h as compared with a standard care systolic blood pressure target of 130-185 mm Hg. Notably, these results are applicable to patients with successful reperfusion and systolic blood pressures of more than 130 mm Hg at the end of procedure. Further studies are needed to understand the association between blood pressure and outcomes after reperfusion.

fundingFrench Health Ministry.

Indexed as

AgedAged, 80 and overAntihypertensive AgentsBlood PressureCerebral HemorrhageEndovascular ProceduresFemaleHumansHypertensionIschemic StrokeMaleMiddle AgedAntihypertensive Agents

Identifiers

PMID33647246
OpenAlexW3133993978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.